KALA BIO, Inc. Insider Trading Activity
Every SEC Form 4 insider transaction reported for KALA BIO, Inc. (KALA), sourced directly from SEC EDGAR and updated as new filings are accepted.
By Trabud · Insider-trading data from SEC EDGAR
Latest filing:
Compiled automatically from SEC EDGAR Form 4 filings and refreshed daily. Figures count purchases (code P) and sales (code S) only — not grants, option exercises, or gifts. How this page is built. Not investment advice.
Quick Answer
Are KALA insiders buying or selling?
In the last 12 months, KALA BIO, Inc. insiders reported 0 open-market purchases ($0) and 5 sales ($248.7K) — net selling of $248.7K. Since January 2018, Trabud has recorded 89 Form 4 filings for KALA: 17 buys ($181.6M) and 72 sells ($4.2M).
Source: SEC EDGAR Form 4
Key Statistics (January 2018 – Oct 25, 2025)
Total Form 4 filings
89
SEC EDGAR
Insider filers
13
Insider buys (17)
$181.6M
Insider sells (72)
$4.2M
Insider sentiment
Net buyingNet insider flow of $177.4M in net buying since January 2018, and $248.7K in net selling over the last 12 months.
Recent KALA insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 25, 2025 | Mark T Iwicki | Director | Sale | 154.9K | $0.81 | $125.5K | SEC ↗ |
| Oct 25, 2025 | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale | 33.2K | $0.83 | $27.5K | SEC ↗ |
| Oct 25, 2025 | Todd Bazemore | Director | Sale | 47.8K | $0.83 | $39.6K | SEC ↗ |
| Oct 25, 2025 | Romulus K Brazzell | Head of Research and Development and Chief Medical Officer | Sale | 46.7K | $0.83 | $38.8K | SEC ↗ |
| Oct 25, 2025 | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale | 20.8K | $0.83 | $17.3K | SEC ↗ |
| Oct 2, 2025 | Felix Baker | Other | Sale | 730.4K | $1.45 | $1.1M | SEC ↗ |
| Jun 27, 2025 | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale | 4.5K | $4.01 | $18.1K | SEC ↗ |
| Jun 27, 2025 | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale | 3.6K | $4.01 | $14.6K | SEC ↗ |
| Jun 27, 2025 | Todd Bazemore | Interim Chief Executive Officer, President and Chief Operating Officer | Sale | 4.1K | $4.01 | $16.3K | SEC ↗ |
| Jun 27, 2025 | Romulus K Brazzell | Head of Research and Development and Chief Medical Officer | Sale | 5.3K | $4.01 | $21.1K | SEC ↗ |
| Jun 27, 2025 | Mark T Iwicki | Director | Sale | 13.2K | $4.01 | $53.0K | SEC ↗ |
| Jun 6, 2025 | Mark T Iwicki | Director | Sale | 10.9K | $3.74 | $40.6K | SEC ↗ |
| Jun 5, 2025 | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale | 730 | $3.74 | $2.7K | SEC ↗ |
| Jun 5, 2025 | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale | 2.9K | $3.74 | $10.7K | SEC ↗ |
| Jun 5, 2025 | Todd Bazemore | Interim Chief Executive Officer, President and Chief Operating Officer | Sale | 3.4K | $3.74 | $12.7K | SEC ↗ |
| Jun 5, 2025 | Romulus K Brazzell | Head of Research and Development and Chief Medical Officer | Sale | 3.7K | $3.74 | $13.8K | SEC ↗ |
| Jun 5, 2025 | Mark T Iwicki | Director | Purchase | 10.9K | $3.74 | $40.6K | SEC ↗ |
| Jan 8, 2025 | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale | 2.0K | $7.63 | $15.4K | SEC ↗ |
| Jan 8, 2025 | Todd Bazemore | President and Chief Operating Officer | Sale | 2.0K | $7.63 | $15.2K | SEC ↗ |
| Jan 8, 2025 | Romulus K Brazzell | Head of Research and Development and Chief Medical Officer | Sale | 2.4K | $7.63 | $18.7K | SEC ↗ |
| Jan 8, 2025 | Mark T Iwicki | CHIEF EXECUTIVE OFFICER | Sale | 5.8K | $7.63 | $44.1K | SEC ↗ |
| Jan 8, 2025 | Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale | 1.7K | $7.63 | $13.0K | SEC ↗ |
| Dec 31, 2024 | Felix Baker | 10% Owner | Purchase | 310.6K | $6.44 | $2.0M | SEC ↗ |
| Jun 28, 2024 | Todd Bazemore | President and Chief Operating Officer | Sale | 4.7K | $4.75 | $22.1K | SEC ↗ |
| Jun 28, 2024 | Darius Kharabi | CHIEF BUSINESS OFFICER | Sale | 5.2K | $4.75 | $24.5K | SEC ↗ |
Showing the 25 most recent of 89 Form 4 filings for KALA BIO, Inc..
Most active KALA insiders
- Todd Bazemore15 filings
- Mark T Iwicki14 filings
- Mary Reumuth13 filings
- Romulus K Brazzell13 filings
- Darius Kharabi7 filings
Ask anything about KALA insider activity
Use Trabud's AI agent to query KALA BIO, Inc.'s Form 4 history in plain English — "Show me KALA CEO purchases this year" or compare it against any other ticker.
Open the AI agentKALA insider trading FAQ
Are KALA BIO, Inc. insiders buying or selling?
In the last 12 months, KALA BIO, Inc. insiders reported 0 open-market purchases ($0) and 5 sales ($248.7K) — net selling of $248.7K. Since January 2018, Trabud has recorded 89 Form 4 filings for KALA: 17 buys ($181.6M) and 72 sells ($4.2M). Over the full record that is net buying of $177.4M.
How many insiders trade KALA stock?
13 distinct insider filers — officers, directors, 10%+ owners, and investment groups filing jointly — have reported Form 4 transactions for KALA BIO, Inc.. The most recent filing was accepted on Oct 25, 2025.
Where does Trabud get KALA insider trading data?
All KALA insider trading data comes directly from official SEC EDGAR Form 4 filings, which corporate insiders must submit within two business days of a transaction under Section 16(a) of the Securities Exchange Act of 1934.